Skip to main content
Top
Published in: Arthritis Research & Therapy 1/2018

Open Access 01-12-2018 | Research article

Longitudinal stability of fibromyalgia symptom clusters

Authors: Tanya L. Hoskin, Mary O. Whipple, Sanjeev Nanda, Ann Vincent

Published in: Arthritis Research & Therapy | Issue 1/2018

Login to get access

Abstract

Background

Using self-report questionnaires of key fibromyalgia symptom domains (pain, fatigue, sleep disturbance, function, stiffness, dyscognition, depression, and anxiety), we previously identified four unique symptom clusters. The purpose of this study was to examine the stability of fibromyalgia symptom clusters between baseline and 2-year follow-up.

Methods

Women with a diagnosis of fibromyalgia completed the Brief Pain Inventory, Profile of Mood States, Medical Outcomes Study Sleep measure, Multidimensional Fatigue Inventory, Multiple Ability Self-Report Questionnaire, Revised Fibromyalgia Impact Questionnaire, and the 36-Item Short Form Survey Instrument at baseline. Follow-up measures were completed approximately 2 years later. The hierarchical agglomerative clustering algorithm previously developed was applied; agreement between baseline and follow-up was assessed with the κ statistic.

Results

Among 433 participants, the mean age was 56 (range 20–85) years. The median Revised Fibromyalgia Impact Questionnaire total score was 57 (range 8–96). More than half of participants (58%) remained in the same cluster at follow-up as at baseline, which represented moderate agreement between baseline and follow-up (κ = 0.44, 95% confidence interval (CI) 0.37–0.50). Only two patients changed from high symptom intensity to low symptom intensity; similarly, only three moved from low to high.

Conclusions

Fibromyalgia patients classified into four unique symptom clusters based on the key domains of pain, fatigue, sleep disturbance, function, stiffness, dyscognition, depression, and anxiety showed moderate stability in cluster assignment after 2 years. Few patients moved between the two extremes of severity, and it was slightly more common to move to a lower symptom level than to worsen.

Trial registration

Not applicable.
Literature
1.
go back to reference Mease PJ, Arnold LM, Crofford LJ, Williams DA, Russell IJ, Humphrey L, Abetz L, Martin SA. Identifying the clinical domains of fibromyalgia: contributions from clinician and patient Delphi exercises. Arthritis Rheum. 2008;59(7):952–60.CrossRefPubMed Mease PJ, Arnold LM, Crofford LJ, Williams DA, Russell IJ, Humphrey L, Abetz L, Martin SA. Identifying the clinical domains of fibromyalgia: contributions from clinician and patient Delphi exercises. Arthritis Rheum. 2008;59(7):952–60.CrossRefPubMed
2.
go back to reference Vincent A, Hoskin TL, Whipple MO, Clauw DJ, Barton DL, Benzo RP, Williams DA. OMERACT-based fibromyalgia symptom subgroups: an exploratory cluster analysis. Arthritis Res Ther. 2014;16(5):463.CrossRefPubMedPubMedCentral Vincent A, Hoskin TL, Whipple MO, Clauw DJ, Barton DL, Benzo RP, Williams DA. OMERACT-based fibromyalgia symptom subgroups: an exploratory cluster analysis. Arthritis Res Ther. 2014;16(5):463.CrossRefPubMedPubMedCentral
3.
go back to reference de Souza JB, Goffaux P, Julien N, Potvin S, Charest J, Marchand S. Fibromyalgia subgroups: profiling distinct subgroups using the Fibromyalgia Impact Questionnaire. A preliminary study. Rheumatol Int. 2009;29(5):509–15.CrossRefPubMed de Souza JB, Goffaux P, Julien N, Potvin S, Charest J, Marchand S. Fibromyalgia subgroups: profiling distinct subgroups using the Fibromyalgia Impact Questionnaire. A preliminary study. Rheumatol Int. 2009;29(5):509–15.CrossRefPubMed
4.
5.
go back to reference Loevinger BL, Shirtcliff EA, Muller D, Alonso C, Coe CL. Delineating psychological and biomedical profiles in a heterogeneous fibromyalgia population using cluster analysis. Clin Rheumatol. 2012;31(4):677–85.CrossRefPubMed Loevinger BL, Shirtcliff EA, Muller D, Alonso C, Coe CL. Delineating psychological and biomedical profiles in a heterogeneous fibromyalgia population using cluster analysis. Clin Rheumatol. 2012;31(4):677–85.CrossRefPubMed
6.
go back to reference Docampo E, Collado A, Escaramis G, Carbonell J, Rivera J, Vidal J, Alegre J, Rabionet R, Estivill X. Cluster analysis of clinical data identifies fibromyalgia subgroups. PLoS One. 2013;8(9):e74873.CrossRefPubMedPubMedCentral Docampo E, Collado A, Escaramis G, Carbonell J, Rivera J, Vidal J, Alegre J, Rabionet R, Estivill X. Cluster analysis of clinical data identifies fibromyalgia subgroups. PLoS One. 2013;8(9):e74873.CrossRefPubMedPubMedCentral
7.
go back to reference Yim YR, Lee KE, Park DJ, Kim SH, Nah SS, Lee JH, Kim SK, Lee YA, Hong SJ, Kim HS, et al. Identifying fibromyalgia subgroups using cluster analysis: relationships with clinical variables. Eur J Pain. 2017;21(2):374–84.CrossRefPubMed Yim YR, Lee KE, Park DJ, Kim SH, Nah SS, Lee JH, Kim SK, Lee YA, Hong SJ, Kim HS, et al. Identifying fibromyalgia subgroups using cluster analysis: relationships with clinical variables. Eur J Pain. 2017;21(2):374–84.CrossRefPubMed
8.
go back to reference Walitt B, Fitzcharles MA, Hassett AL, Katz RS, Hauser W, Wolfe F. The longitudinal outcome of fibromyalgia: a study of 1555 patients. J Rheumatol. 2011;38(10):2238–46.CrossRefPubMed Walitt B, Fitzcharles MA, Hassett AL, Katz RS, Hauser W, Wolfe F. The longitudinal outcome of fibromyalgia: a study of 1555 patients. J Rheumatol. 2011;38(10):2238–46.CrossRefPubMed
9.
go back to reference Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Hauser W, Katz RS, Mease P, Russell AS, Russell IJ, Winfield JB. Fibromyalgia criteria and severity scales for clinical and epidemiological studies: a modification of the ACR Preliminary Diagnostic Criteria for Fibromyalgia. J Rheumatol. 2011;38(6):1113–22.CrossRefPubMed Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Hauser W, Katz RS, Mease P, Russell AS, Russell IJ, Winfield JB. Fibromyalgia criteria and severity scales for clinical and epidemiological studies: a modification of the ACR Preliminary Diagnostic Criteria for Fibromyalgia. J Rheumatol. 2011;38(6):1113–22.CrossRefPubMed
10.
go back to reference Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singap. 1994;23(2):129–38.PubMed Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singap. 1994;23(2):129–38.PubMed
11.
go back to reference McNair DM, Lorr M, Droppleman LF. EdITS manual for the profile of mood states. San Diego, California: Educational and Industrial Testing Service; 1992. McNair DM, Lorr M, Droppleman LF. EdITS manual for the profile of mood states. San Diego, California: Educational and Industrial Testing Service; 1992.
12.
go back to reference Cappelleri JC, Bushmakin AG, McDermott AM, Dukes E, Sadosky A, Petrie CD, Martin S. Measurement properties of the Medical Outcomes Study Sleep Scale in patients with fibromyalgia. Sleep Med. 2009;10(7):766–70.CrossRefPubMed Cappelleri JC, Bushmakin AG, McDermott AM, Dukes E, Sadosky A, Petrie CD, Martin S. Measurement properties of the Medical Outcomes Study Sleep Scale in patients with fibromyalgia. Sleep Med. 2009;10(7):766–70.CrossRefPubMed
13.
go back to reference Smets EM, Garssen B, Bonke B, De Haes JC. The Multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue. J Psychosom Res. 1995;39(3):315–25.CrossRefPubMed Smets EM, Garssen B, Bonke B, De Haes JC. The Multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue. J Psychosom Res. 1995;39(3):315–25.CrossRefPubMed
14.
go back to reference Seidenberg M, Haltiner A, Taylor MA, Hermann BB, Wyler A. Development and validation of a Multiple Ability Self-Report Questionnaire. J Clin Exp Neuropsychol. 1994;16(1):93–104.CrossRefPubMed Seidenberg M, Haltiner A, Taylor MA, Hermann BB, Wyler A. Development and validation of a Multiple Ability Self-Report Questionnaire. J Clin Exp Neuropsychol. 1994;16(1):93–104.CrossRefPubMed
15.
go back to reference Bennett RM, Friend R, Jones KD, Ward R, Han BK, Ross RL. The Revised Fibromyalgia Impact Questionnaire (FIQR): validation and psychometric properties. Arthritis Res Ther. 2009;11(4):R120.CrossRefPubMedPubMedCentral Bennett RM, Friend R, Jones KD, Ward R, Han BK, Ross RL. The Revised Fibromyalgia Impact Questionnaire (FIQR): validation and psychometric properties. Arthritis Res Ther. 2009;11(4):R120.CrossRefPubMedPubMedCentral
16.
go back to reference Ware JE Jr. SF-36 health survey update. Spine (Phila Pa 1976). 2000;25(24):3130–9.CrossRef Ware JE Jr. SF-36 health survey update. Spine (Phila Pa 1976). 2000;25(24):3130–9.CrossRef
17.
go back to reference Williams DA, Arnold LM. Measures of fibromyalgia: Fibromyalgia Impact Questionnaire (FIQ), Brief Pain Inventory (BPI), Multidimensional Fatigue Inventory (MFI-20), Medical Outcomes Study (MOS) Sleep Scale, and Multiple Ability Self-Report Questionnaire (MASQ). Arthritis Care Res. 2011;63(Suppl 11):S86–97.CrossRef Williams DA, Arnold LM. Measures of fibromyalgia: Fibromyalgia Impact Questionnaire (FIQ), Brief Pain Inventory (BPI), Multidimensional Fatigue Inventory (MFI-20), Medical Outcomes Study (MOS) Sleep Scale, and Multiple Ability Self-Report Questionnaire (MASQ). Arthritis Care Res. 2011;63(Suppl 11):S86–97.CrossRef
18.
go back to reference Vincent A, McAllister SJ, Singer W, Toussaint LL, Sletten DM, Whipple MO, Low PA. A report of the autonomic symptom profile in patients with fibromyalgia. J Clin Rheumatol. 2014;20(2):106–8.CrossRefPubMedPubMedCentral Vincent A, McAllister SJ, Singer W, Toussaint LL, Sletten DM, Whipple MO, Low PA. A report of the autonomic symptom profile in patients with fibromyalgia. J Clin Rheumatol. 2014;20(2):106–8.CrossRefPubMedPubMedCentral
19.
go back to reference Arnold LM, Rosen A, Pritchett YL, D'Souza DN, Goldstein DJ, Iyengar S, Wernicke JF. A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain. 2005;119(1–3):5–15.CrossRefPubMed Arnold LM, Rosen A, Pritchett YL, D'Souza DN, Goldstein DJ, Iyengar S, Wernicke JF. A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain. 2005;119(1–3):5–15.CrossRefPubMed
20.
go back to reference Chappell AS, Bradley LA, Wiltse C, Detke MJ, D'Souza DN, Spaeth M. A six-month double-blind, placebo-controlled, randomized clinical trial of duloxetine for the treatment of fibromyalgia. Int J Gen Med. 2008;1:91–102.CrossRefPubMed Chappell AS, Bradley LA, Wiltse C, Detke MJ, D'Souza DN, Spaeth M. A six-month double-blind, placebo-controlled, randomized clinical trial of duloxetine for the treatment of fibromyalgia. Int J Gen Med. 2008;1:91–102.CrossRefPubMed
21.
go back to reference Mease PJ, Spaeth M, Clauw DJ, Arnold LM, Bradley LA, Russell IJ, Kajdasz DK, Walker DJ, Chappell AS. Estimation of minimum clinically important difference for pain in fibromyalgia. Arthritis Care Res. 2011;63(6):821–6.CrossRef Mease PJ, Spaeth M, Clauw DJ, Arnold LM, Bradley LA, Russell IJ, Kajdasz DK, Walker DJ, Chappell AS. Estimation of minimum clinically important difference for pain in fibromyalgia. Arthritis Care Res. 2011;63(6):821–6.CrossRef
22.
go back to reference Russell IJ, Mease PJ, Smith TR, Kajdasz DK, Wohlreich MM, Detke MJ, Walker DJ, Chappell AS, Arnold LM. Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial. Pain. 2008;136(3):432–44.CrossRefPubMed Russell IJ, Mease PJ, Smith TR, Kajdasz DK, Wohlreich MM, Detke MJ, Walker DJ, Chappell AS, Arnold LM. Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial. Pain. 2008;136(3):432–44.CrossRefPubMed
23.
go back to reference Bourgeois A, LeUnes A, Meyers M. Full-scale and short-form of the Profile of Mood States: a factor analytic comparison. J Sport Behav. 2010;33(4):355–76. Bourgeois A, LeUnes A, Meyers M. Full-scale and short-form of the Profile of Mood States: a factor analytic comparison. J Sport Behav. 2010;33(4):355–76.
24.
go back to reference Malin K, Littlejohn GO. Psychological control is a key modulator of fibromyalgia symptoms and comorbidities. J Pain Res. 2012;5:463–71.PubMedPubMedCentral Malin K, Littlejohn GO. Psychological control is a key modulator of fibromyalgia symptoms and comorbidities. J Pain Res. 2012;5:463–71.PubMedPubMedCentral
25.
go back to reference Katz RS, Heard AR, Mills M, Leavitt F. The prevalence and clinical impact of reported cognitive difficulties (fibrofog) in patients with rheumatic disease with and without fibromyalgia. J Clin Rheumatol. 2004;10(2):53–8.CrossRefPubMed Katz RS, Heard AR, Mills M, Leavitt F. The prevalence and clinical impact of reported cognitive difficulties (fibrofog) in patients with rheumatic disease with and without fibromyalgia. J Clin Rheumatol. 2004;10(2):53–8.CrossRefPubMed
26.
go back to reference Arnold LM, Russell IJ, Diri EW, Duan WR, Young JP Jr, Sharma U, Martin SA, Barrett JA, Haig G. A 14-week, randomized, double-blinded, placebo-controlled monotherapy trial of pregabalin in patients with fibromyalgia. J Pain. 2008;9(9):792–805.CrossRefPubMed Arnold LM, Russell IJ, Diri EW, Duan WR, Young JP Jr, Sharma U, Martin SA, Barrett JA, Haig G. A 14-week, randomized, double-blinded, placebo-controlled monotherapy trial of pregabalin in patients with fibromyalgia. J Pain. 2008;9(9):792–805.CrossRefPubMed
27.
go back to reference Crofford LJ, Rowbotham MC, Mease PJ, Russell IJ, Dworkin RH, Corbin AE, Young JP Jr, LK LM, Martin SA, Sharma U, et al. Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2005;52(4):1264–73.CrossRefPubMed Crofford LJ, Rowbotham MC, Mease PJ, Russell IJ, Dworkin RH, Corbin AE, Young JP Jr, LK LM, Martin SA, Sharma U, et al. Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2005;52(4):1264–73.CrossRefPubMed
28.
go back to reference Martin S, Chandran A, Zografos L, Zlateva G. Evaluation of the impact of fibromyalgia on patients' sleep and the content validity of two sleep scales. Health Qual Life Outcomes. 2009;7:64.CrossRefPubMedPubMedCentral Martin S, Chandran A, Zografos L, Zlateva G. Evaluation of the impact of fibromyalgia on patients' sleep and the content validity of two sleep scales. Health Qual Life Outcomes. 2009;7:64.CrossRefPubMedPubMedCentral
29.
go back to reference Clauw DJ, Mease P, Palmer RH, Gendreau RM, Wang Y. Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial. Clin Ther. 2008;30(11):1988–2004.CrossRefPubMed Clauw DJ, Mease P, Palmer RH, Gendreau RM, Wang Y. Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial. Clin Ther. 2008;30(11):1988–2004.CrossRefPubMed
30.
go back to reference Arnold LM, Wang F, Ahl J, Gaynor PJ, Wohlreich MM. Improvement in multiple dimensions of fatigue in patients with fibromyalgia treated with duloxetine: secondary analysis of a randomized, placebo-controlled trial. Arthritis Res Ther. 2011;13(3):R86.CrossRefPubMedPubMedCentral Arnold LM, Wang F, Ahl J, Gaynor PJ, Wohlreich MM. Improvement in multiple dimensions of fatigue in patients with fibromyalgia treated with duloxetine: secondary analysis of a randomized, placebo-controlled trial. Arthritis Res Ther. 2011;13(3):R86.CrossRefPubMedPubMedCentral
31.
go back to reference Owen RT. Milnacipran hydrochloride: its efficacy, safety and tolerability profile in fibromyalgia syndrome. Drugs Today (Barc). 2008;44(9):653–60.CrossRef Owen RT. Milnacipran hydrochloride: its efficacy, safety and tolerability profile in fibromyalgia syndrome. Drugs Today (Barc). 2008;44(9):653–60.CrossRef
32.
go back to reference Branco JC, Bannwarth B, Failde I, Abello Carbonell J, Blotman F, Spaeth M, Saraiva F, Nacci F, Thomas E, Caubere JP, et al. Prevalence of fibromyalgia: a survey in five European countries. Semin Arthritis Rheum. 2010;39(6):448–53.CrossRefPubMed Branco JC, Bannwarth B, Failde I, Abello Carbonell J, Blotman F, Spaeth M, Saraiva F, Nacci F, Thomas E, Caubere JP, et al. Prevalence of fibromyalgia: a survey in five European countries. Semin Arthritis Rheum. 2010;39(6):448–53.CrossRefPubMed
33.
go back to reference Mease PJ, Clauw DJ, Gendreau RM, Rao SG, Kranzler J, Chen W, Palmer RH. The efficacy and safety of milnacipran for treatment of fibromyalgia. A randomized, double-blind, placebo-controlled trial. J Rheumatol. 2009;36(2):398–409.CrossRefPubMed Mease PJ, Clauw DJ, Gendreau RM, Rao SG, Kranzler J, Chen W, Palmer RH. The efficacy and safety of milnacipran for treatment of fibromyalgia. A randomized, double-blind, placebo-controlled trial. J Rheumatol. 2009;36(2):398–409.CrossRefPubMed
34.
go back to reference Arnold LM, Hess EV, Hudson JI, Welge JA, Berno SE, Keck PE Jr. A randomized, placebo-controlled, double-blind, flexible-dose study of fluoxetine in the treatment of women with fibromyalgia. Am J Med. 2002;112(3):191–7.CrossRefPubMed Arnold LM, Hess EV, Hudson JI, Welge JA, Berno SE, Keck PE Jr. A randomized, placebo-controlled, double-blind, flexible-dose study of fluoxetine in the treatment of women with fibromyalgia. Am J Med. 2002;112(3):191–7.CrossRefPubMed
35.
go back to reference Arnold LM, Gendreau RM, Palmer RH, Gendreau JF, Wang Y. Efficacy and safety of milnacipran 100 mg/day in patients with fibromyalgia: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2010;62(9):2745–56.CrossRefPubMed Arnold LM, Gendreau RM, Palmer RH, Gendreau JF, Wang Y. Efficacy and safety of milnacipran 100 mg/day in patients with fibromyalgia: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2010;62(9):2745–56.CrossRefPubMed
36.
go back to reference Da Costa D, Dobkin PL, Fitzcharles MA, Fortin PR, Beaulieu A, Zummer M, Senecal JL, Goulet JR, Rich E, Choquette D, et al. Determinants of health status in fibromyalgia: a comparative study with systemic lupus erythematosus. J Rheumatol. 2000;27(2):365–72.PubMed Da Costa D, Dobkin PL, Fitzcharles MA, Fortin PR, Beaulieu A, Zummer M, Senecal JL, Goulet JR, Rich E, Choquette D, et al. Determinants of health status in fibromyalgia: a comparative study with systemic lupus erythematosus. J Rheumatol. 2000;27(2):365–72.PubMed
37.
go back to reference Neumann L, Berzak A, Buskila D. Measuring health status in Israeli patients with fibromyalgia syndrome and widespread pain and healthy individuals: utility of the short form 36-item health survey (SF-36). Semin Arthritis Rheum. 2000;29(6):400–8.CrossRefPubMed Neumann L, Berzak A, Buskila D. Measuring health status in Israeli patients with fibromyalgia syndrome and widespread pain and healthy individuals: utility of the short form 36-item health survey (SF-36). Semin Arthritis Rheum. 2000;29(6):400–8.CrossRefPubMed
38.
go back to reference Tuzun EH, Albayrak G, Eker L, Sozay S, Daskapan A. A comparison study of quality of life in women with fibromyalgia and myofascial pain syndrome. Disabil Rehabil. 2004;26(4):198–202.CrossRefPubMed Tuzun EH, Albayrak G, Eker L, Sozay S, Daskapan A. A comparison study of quality of life in women with fibromyalgia and myofascial pain syndrome. Disabil Rehabil. 2004;26(4):198–202.CrossRefPubMed
39.
go back to reference Arnold LM, Williams DA, Hudson JI, Martin SA, Clauw DJ, Crofford LJ, Wang F, Emir B, Lai C, Zablocki R, et al. Development of responder definitions for fibromyalgia clinical trials. Arthritis Rheum. 2012;64(3):885–94.CrossRefPubMedPubMedCentral Arnold LM, Williams DA, Hudson JI, Martin SA, Clauw DJ, Crofford LJ, Wang F, Emir B, Lai C, Zablocki R, et al. Development of responder definitions for fibromyalgia clinical trials. Arthritis Rheum. 2012;64(3):885–94.CrossRefPubMedPubMedCentral
40.
go back to reference Arnold LM, Clauw DJ. Challenges of implementing fibromyalgia treatment guidelines in current clinical practice. Postgrad Med. 2017;129(7):709–14.CrossRefPubMed Arnold LM, Clauw DJ. Challenges of implementing fibromyalgia treatment guidelines in current clinical practice. Postgrad Med. 2017;129(7):709–14.CrossRefPubMed
41.
go back to reference Macfarlane GJ, Kronisch C, Dean LE, Atzeni F, Hauser W, Fluss E, Choy E, Kosek E, Amris K, Branco J, et al. EULAR revised recommendations for the management of fibromyalgia. Ann Rheum Dis. 2017;76(2):318–28.CrossRefPubMed Macfarlane GJ, Kronisch C, Dean LE, Atzeni F, Hauser W, Fluss E, Choy E, Kosek E, Amris K, Branco J, et al. EULAR revised recommendations for the management of fibromyalgia. Ann Rheum Dis. 2017;76(2):318–28.CrossRefPubMed
42.
go back to reference Del Pozo-Cruz J, Alfonso-Rosa RM, Castillo-Cuerva A, Sanudo B, Nolan P, Del Pozo-Cruz B. Depression symptoms are associated with key health outcomes in women with fibromyalgia: a cross-sectional study. Int J Rheum Dis. 2017;20(7):798–808.CrossRefPubMed Del Pozo-Cruz J, Alfonso-Rosa RM, Castillo-Cuerva A, Sanudo B, Nolan P, Del Pozo-Cruz B. Depression symptoms are associated with key health outcomes in women with fibromyalgia: a cross-sectional study. Int J Rheum Dis. 2017;20(7):798–808.CrossRefPubMed
43.
go back to reference Bateman L, Sarzi-Puttini P, Burbridge CL, Landen JW, Masters ET, Bhadra Brown P, Scavone JM, Emir B, Vissing RS, Clair AG, et al. Burden of illness in fibromyalgia patients with comorbid depression. Clin Exp Rheumatol. 2016;34(2 Suppl 96):S106–13.PubMed Bateman L, Sarzi-Puttini P, Burbridge CL, Landen JW, Masters ET, Bhadra Brown P, Scavone JM, Emir B, Vissing RS, Clair AG, et al. Burden of illness in fibromyalgia patients with comorbid depression. Clin Exp Rheumatol. 2016;34(2 Suppl 96):S106–13.PubMed
44.
go back to reference Chang MH, Hsu JW, Huang KL, Su TP, Bai YM, Li CT, Yang AC, Chang WH, Chen TJ, Tsai SJ, et al. Bidirectional association between depression and fibromyalgia syndrome: a nationwide longitudinal study. J Pain. 2015;16(9):895–902.CrossRefPubMed Chang MH, Hsu JW, Huang KL, Su TP, Bai YM, Li CT, Yang AC, Chang WH, Chen TJ, Tsai SJ, et al. Bidirectional association between depression and fibromyalgia syndrome: a nationwide longitudinal study. J Pain. 2015;16(9):895–902.CrossRefPubMed
45.
go back to reference Häuser W, Perrot S, Clauw DJ, Fitzcharles M-A. Unravelling fibromyalgia—steps toward individualized management. J Pain. 2018;19(2):125–34. Häuser W, Perrot S, Clauw DJ, Fitzcharles M-A. Unravelling fibromyalgia—steps toward individualized management. J Pain. 2018;19(2):125–34.
46.
go back to reference McKinley BT, Mulhall BP, Jackson JL. Perceived versus actual medication regimens among internal medicine patients. Mil Med. 2004;169(6):451–4.CrossRefPubMed McKinley BT, Mulhall BP, Jackson JL. Perceived versus actual medication regimens among internal medicine patients. Mil Med. 2004;169(6):451–4.CrossRefPubMed
47.
go back to reference Whipple MO, McAllister SJ, Oh TH, Luedtke CA, Toussaint LL, Vincent A. Construction of a US fibromyalgia registry using the Fibromyalgia Research Survey criteria. Clin Transl Sci. 2013;6(5):398–9.CrossRefPubMedPubMedCentral Whipple MO, McAllister SJ, Oh TH, Luedtke CA, Toussaint LL, Vincent A. Construction of a US fibromyalgia registry using the Fibromyalgia Research Survey criteria. Clin Transl Sci. 2013;6(5):398–9.CrossRefPubMedPubMedCentral
Metadata
Title
Longitudinal stability of fibromyalgia symptom clusters
Authors
Tanya L. Hoskin
Mary O. Whipple
Sanjeev Nanda
Ann Vincent
Publication date
01-12-2018
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue 1/2018
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/s13075-018-1532-0

Other articles of this Issue 1/2018

Arthritis Research & Therapy 1/2018 Go to the issue